The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: A study of 94 Japanese men

Cancer

Volumn 94, Issue 6, 2002, Pages 1692-1698

  Vollmer, Robin T ^a   Egawa, Shin ^b   Kuwao, Sadahito ^b   Baba, Shiro ^b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Model; Prostate carcinoma; Prostate specific antigen (PSA); Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; DIAGNOSTIC VALUE; EARLY CANCER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; JAPAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CARCINOMA; STATISTICAL MODEL; SURVIVAL RATE; VELOCITY;

AGED; AGED, 80 AND OVER; CARCINOMA; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 0037086468     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10443     Document Type: Article

References (26)

1. Serum prostate-specific antigen: The most useful tumor marker
2. Results of radical prostatectomy in men with clinically localized prostate cancer. Multi-institutional pooled analysis
3. Radiation therapy for clinically localized prostate cancer. A multi-institutional pooled analysis
4. Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the prostate cancer center outcomes study
5. The natural history of clinical prostate carcinoma
6. Results of conservative management of clinically localized prostate cancer
7. Deferred treatment of clinically localized low-grade prostate cancer: Actual 10-year and projected 15-year follow-up of the Karolinska series
8. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden
9. Long-term survival among men with conservatively treated localized prostate cancer
10. Outcome research after radical retropubic prostatectomy for prostate cancer
11. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute
12. The prostate cancer intervention versus observation trial: A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer
13. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
14. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate cancer
15. Serial prostate specific antigen measurements and progression in untreated confined (stages TO to 3NxM0, grades 1 to 3) carcinoma of the prostate
16. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy
17. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer
18. The dynamics of prostate-specific antigen in hormone refractory prostate cancer. An analysis of Cancer and Leukemia Group B study 9181 of megestrol acetate
19. A prognostic score for hormone refractory prostate cancer: Analysis of two Cancer and Leukemia Group B studies
20. Histologic grading of prostate cancer: A perspective
21. Urological tumors - Prostate
22. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma
23. Estimation of prostatic growth using serial prostate -specific antigen measurements in men with and without prostate disease
24. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer